Joanne Jenkins Lager - 11 Mar 2022 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Medical Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Issuer symbol
ITOS
Transactions as of
11 Mar 2022
Net transactions value
-$110,985
Form type
4
Filing time
14 Mar 2022, 20:01:27 UTC
Previous filing
14 Feb 2022
Next filing
10 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Options Exercise $15,050 +3,500 $4.30 3,500 11 Mar 2022 Direct
transaction ITOS Common Stock Sale $126,035 -3,500 -100% $36.01 0 11 Mar 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Award $0 +85,000 $0.000000 85,000 11 Mar 2022 Common Stock 85,000 $36.21 Direct F1
transaction ITOS Stock Option (Right to Buy) Options Exercise $0 -3,500 -1.9% $0.000000 178,938 11 Mar 2022 Common Stock 3,500 $4.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option shall vest over 4 years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer.
F2 One-fourth of the shares subject to the stock option vested on April 1, 2020. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date